546 related articles for article (PubMed ID: 26053162)
1. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Deger JM; Gerson JE; Kayed R
Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?
Dennissen FJ; Kholod N; van Leeuwen FW
Prog Neurobiol; 2012 Feb; 96(2):190-207. PubMed ID: 22270043
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM; Fischer DF; Ovaa H; Scheper W
Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
[TBL] [Abstract][Full Text] [Related]
4. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
Gadad BS; Britton GB; Rao KS
J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
[TBL] [Abstract][Full Text] [Related]
5. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
Ciechanover A; Kwon YT
Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
[TBL] [Abstract][Full Text] [Related]
6. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies.
Kumar D; Ambasta RK; Kumar P
Ageing Res Rev; 2020 Aug; 61():101078. PubMed ID: 32407951
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of neurotoxic tau oligomers.
Lasagna-Reeves CA; Castillo-Carranza DL; Guerrero-Muoz MJ; Jackson GR; Kayed R
Biochemistry; 2010 Nov; 49(47):10039-41. PubMed ID: 21047142
[TBL] [Abstract][Full Text] [Related]
9. Proteasome Subunits Involved in Neurodegenerative Diseases.
Fernández-Cruz I; Reynaud E
Arch Med Res; 2021 Jan; 52(1):1-14. PubMed ID: 32962866
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
Ross CA; Pickart CM
Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
[TBL] [Abstract][Full Text] [Related]
11. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
Thibaudeau TA; Anderson RT; Smith DM
Nat Commun; 2018 Mar; 9(1):1097. PubMed ID: 29545515
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities.
Schmidt MF; Gan ZY; Komander D; Dewson G
Cell Death Differ; 2021 Feb; 28(2):570-590. PubMed ID: 33414510
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.
Huang Q; Figueiredo-Pereira ME
Apoptosis; 2010 Nov; 15(11):1292-311. PubMed ID: 20131003
[TBL] [Abstract][Full Text] [Related]
14. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.
Dorval V; Fraser PE
J Biol Chem; 2006 Apr; 281(15):9919-24. PubMed ID: 16464864
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
[TBL] [Abstract][Full Text] [Related]
16. Failure of ubiquitin proteasome system: risk for neurodegenerative diseases.
Zheng C; Geetha T; Babu JR
Neurodegener Dis; 2014; 14(4):161-75. PubMed ID: 25413678
[TBL] [Abstract][Full Text] [Related]
17. Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes.
Ayyadevara S; Balasubramaniam M; Gao Y; Yu LR; Alla R; Shmookler Reis R
Aging Cell; 2015 Feb; 14(1):35-48. PubMed ID: 25510159
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.
Opattova A; Cente M; Novak M; Filipcik P
Gen Physiol Biophys; 2015 Oct; 34(4):337-52. PubMed ID: 26221742
[TBL] [Abstract][Full Text] [Related]
19. The Ubiquitin System in Alzheimer's Disease.
Harris LD; Jasem S; Licchesi JDF
Adv Exp Med Biol; 2020; 1233():195-221. PubMed ID: 32274758
[TBL] [Abstract][Full Text] [Related]
20. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.
Luo HB; Xia YY; Shu XJ; Liu ZC; Feng Y; Liu XH; Yu G; Yin G; Xiong YS; Zeng K; Jiang J; Ye K; Wang XC; Wang JZ
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16586-91. PubMed ID: 25378699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
